HUE044182T2 - Gene therapy for the treatment of amyotrophic lateral sclerosis and other spinal disorders - Google Patents

Gene therapy for the treatment of amyotrophic lateral sclerosis and other spinal disorders

Info

Publication number
HUE044182T2
HUE044182T2 HUE12152550A HUE044182T2 HU E044182 T2 HUE044182 T2 HU E044182T2 HU E12152550 A HUE12152550 A HU E12152550A HU E044182 T2 HUE044182 T2 HU E044182T2
Authority
HU
Hungary
Prior art keywords
treatment
gene therapy
lateral sclerosis
amyotrophic lateral
spinal disorders
Prior art date
Application number
Other languages
Hungarian (hu)
Inventor
James Dodge
Lamya Shihabuddin
Catherine R O'riordan
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of HUE044182T2 publication Critical patent/HUE044182T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HUE12152550 2006-06-07 2007-06-07 Gene therapy for the treatment of amyotrophic lateral sclerosis and other spinal disorders HUE044182T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81141906P 2006-06-07 2006-06-07

Publications (1)

Publication Number Publication Date
HUE044182T2 true HUE044182T2 (en) 2019-10-28

Family

ID=38832369

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE07795835A HUE031156T2 (en) 2006-06-07 2007-06-07 Gene therapy for amyotrophic lateral sclerosis and other spinal cord diseases
HUE12152550 HUE044182T2 (en) 2006-06-07 2007-06-07 Gene therapy for the treatment of amyotrophic lateral sclerosis and other spinal disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE07795835A HUE031156T2 (en) 2006-06-07 2007-06-07 Gene therapy for amyotrophic lateral sclerosis and other spinal cord diseases

Country Status (19)

Country Link
US (4) US9034836B2 (en)
EP (3) EP2489733B1 (en)
JP (6) JP2009539847A (en)
CN (1) CN101460621B (en)
AR (2) AR061282A1 (en)
BR (1) BRPI0711965A2 (en)
CA (2) CA3139726C (en)
CY (1) CY1118555T1 (en)
ES (2) ES2725552T3 (en)
HU (2) HUE031156T2 (en)
IL (2) IL195647A (en)
LT (2) LT2489733T (en)
MX (4) MX2008015530A (en)
PL (2) PL2489733T3 (en)
PT (2) PT2029742T (en)
RU (1) RU2008152821A (en)
SI (2) SI2029742T1 (en)
TR (1) TR201906106T4 (en)
WO (1) WO2007146046A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE031156T2 (en) 2006-06-07 2017-06-28 Genzyme Corp Gene therapy for amyotrophic lateral sclerosis and other spinal cord diseases
WO2009089635A1 (en) * 2008-01-16 2009-07-23 Neurodyn, Inc. Treating neurodegenerative diseases with progranulin (pgrn)
CN102272321A (en) 2008-10-31 2011-12-07 神经动力公司 Neurotoxic sterol glycosides
HRP20250897T1 (en) 2009-05-02 2025-09-26 Genzyme Corporation GENE THERAPY FOR NEURODEGENERATE DISORDERS
JP6312436B2 (en) * 2010-11-16 2018-04-18 ニューロダイン ライフ サイエンシズ インコーポレイテッドＮｅｕｒｏｄｙｎ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． Methods and pharmaceutical compositions for increasing the expression and activity of neprilysin
CN103083667A (en) * 2011-11-01 2013-05-08 北京清美联创干细胞科技有限公司 Continuous dosage scheme of olfactory ensheathing cell proliferation reagent
EP2850093B1 (en) 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Therapeutic il-13 polypeptides
CN104619334A (en) 2012-08-09 2015-05-13 利兰斯坦福初级大学董事会 Superkines and synthetic factors: engineered cytokines with novel and enhanced signaling activities
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
CA2889499C (en) 2012-10-24 2019-09-10 Daiichi Sankyo Company, Limited Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis
WO2014084085A1 (en) * 2012-11-28 2014-06-05 国立大学法人名古屋大学 Prophylactic/therapeutic agent for hearing disorder or cerebellar ataxia
MX380973B (en) 2013-05-01 2025-03-12 Genzyme Corp COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY.
EP3024497B1 (en) * 2013-07-26 2021-01-13 University of Iowa Research Foundation Methods and compositions for treating brain diseases
KR101548989B1 (en) 2013-07-30 2015-09-01 광주과학기술원 Screening Methods of a Substance for Preventing or Treating a Joint Disease Using SirT1
EP3049526B1 (en) 2013-09-24 2021-02-24 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
DE102014207498A1 (en) * 2014-04-17 2015-10-22 Universitätsklinikum Hamburg-Eppendorf Viral vector for targeted gene transfer in the brain and spinal cord
RU2716991C2 (en) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Aadc polynucleotides for treating parkinson's disease
US10214731B2 (en) * 2015-05-28 2019-02-26 Cornell University Adeno-associated virus mediated delivery of C1E1 as a therapy for angioedema
CL2015003024A1 (en) 2015-10-09 2016-05-13 Univ Chile Method of genetic treatment using aav-xbp1s / gfp virus, and its use in the prevention and treatment of amyotrophic lateral sclerosis.
EP3377073A4 (en) 2015-11-16 2019-06-26 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR TREATING DISORDERS AND DISEASES USING MOTONURON SURVIVAL PROTEIN (SMN)
US20190328906A1 (en) * 2016-03-02 2019-10-31 The Children's Hospital Of Philadelphia Therapy for frontotemporal dementia
JOP20190200A1 (en) 2017-02-28 2019-08-27 Univ Pennsylvania Compositions useful in treatment of spinal muscular atrophy
PT3589730T (en) 2017-02-28 2024-02-28 Univ Pennsylvania Adeno-associated virus (aav) clade f vector and uses therefor
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CN112501208A (en) 2017-10-03 2021-03-16 普利维尔治疗公司 Gene therapy for lysosomal disorders
BR112020006661A2 (en) 2017-10-03 2020-10-13 Prevail Therapeutics, Inc. gene therapies for liposomal disorders
AU2018346104B2 (en) 2017-10-03 2023-07-27 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
EP3694558B1 (en) * 2017-10-10 2024-04-10 Medicenna Therapeutics Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
KR20210019996A (en) 2018-05-15 2021-02-23 보이저 테라퓨틱스, 인크. Composition and method for the treatment of Parkinson's disease
US12590133B2 (en) 2018-06-01 2026-03-31 The Board Of Trustees Of The Leland Stanford Junior University IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
RU2731514C2 (en) * 2018-12-21 2020-09-03 Селл энд Джин Терапи Лтд Gene-therapeutic dna-vector based on gene-therapeutic dna-vector vtvaf17, carrying target gene selected from shh, ctnnb1, nog, wnt7a gene group to increase level of expression of these target genes, method for production and use thereof, strain escherichia coli scs110-af/vtvaf17-shh, or escherichia coli scs110-af/vtvaf17-ctnnb1, or escherichia coli scs110-af/vtvaf17-nog, or escherichia coli scs110-af/vtvaf17-wnt7a, carrying gene-therapeutic dna vector, method for production thereof, method for industrial production of gene-therapeutic dna vector
WO2020160458A1 (en) * 2019-02-01 2020-08-06 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
BR112021015817A2 (en) * 2019-02-22 2021-10-13 The Trustees Of The University Of Pennsylvania RECOMBINANT ADENO-ASSOCIATED VIRUS FOR ADULT-ONSET NEURODEGENERATION TREATMENT ASSOCIATED WITH GRN
CA3136004A1 (en) 2019-04-10 2020-10-15 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
EP3952924A4 (en) * 2019-04-12 2023-05-24 Encoded Therapeutics, Inc. Compositions and methods for administration of therapeutics
WO2021068242A1 (en) * 2019-10-12 2021-04-15 Shenzhen University An agent that enables sirt7 gene expression and the use thereof
PH12022551598A1 (en) 2019-12-23 2023-11-20 Denali Therapeutics Inc Progranulin variants
WO2023242844A1 (en) * 2022-06-15 2023-12-21 Ramot At Tel-Aviv University Ltd. Method and therapeutic agent for treatment of disease or disorder associated with impaired firing rate and/or mitochondrial calcium homeostasis
CN115323002A (en) * 2022-07-28 2022-11-11 深圳先进技术研究院 Application of gene delivery system in retrograde delivery of gene from brain to spinal cord neuron
CN120590487A (en) * 2025-06-17 2025-09-05 河北医科大学第二医院 A signal peptide, recombinant vector and its application

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8303626D0 (en) 1983-06-23 1983-06-23 Kabigen Ab A RECOMBINANT PLASMID AND A TRANSFORMANT MICROORGANISM, A POLYDOXYREBONUCLEOTIDE SEGMENT, A PROCESS FOR PRODUCING A BIOLOGICALLY ACTIVE PROTEIN, AND THE PROTEIN THUS PRODUCED
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
WO1995013365A1 (en) 1993-11-09 1995-05-18 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
ATE386131T1 (en) 1994-04-13 2008-03-15 Univ Rockefeller AAV-MEDIATED DELIVERY OF DNA INTO CELLS OF THE NERVOUS SYSTEM
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
AU1525797A (en) 1996-04-22 1997-11-12 Medtronic, Inc. Two-stage angled venous cannula
US20040076613A1 (en) * 2000-11-03 2004-04-22 Nicholas Mazarakis Vector system
NZ504847A (en) 1997-12-04 2003-02-28 Genzyme Corp Chimeric protein comprising a hypoxia inducible factor protein and a transcriptional activation domain and pharmaceutical use
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6468524B1 (en) 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US7037493B2 (en) * 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
US7201898B2 (en) * 2000-06-01 2007-04-10 The University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
JP2004516016A (en) 2000-09-18 2004-06-03 ジェンザイム・コーポレイション Expression vector containing hybrid ubiquitin promoter
GB0103998D0 (en) * 2001-02-19 2001-04-04 King S College London Method
JP2002322068A (en) 2001-02-26 2002-11-08 Japan Science & Technology Corp Vascular regeneration promoter
EP1402043A1 (en) * 2001-07-03 2004-03-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of administering vectors to synaptically connected neurons
IL162630A0 (en) 2001-12-21 2005-11-20 Salk Inst For Biological Studi A composition containing a viral vector containinga heterologous gene to be transduced into a neuron
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
AU2003215297A1 (en) * 2002-02-15 2003-09-09 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US20060246036A1 (en) * 2002-09-06 2006-11-02 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
EP1811023A4 (en) 2004-09-29 2009-04-29 Dainippon Sumitomo Pharma Co GENE SPECIFICALLY EXPRESSED IN ES CELLS AND USE OF SAID GENE
EP1878793B1 (en) 2004-11-18 2011-08-24 Tokyo Medical and Dental University Novel protein and preventive/remedy for neurodegenerative disease such as polyglutamine disease using the same
JP5829372B2 (en) 2005-05-02 2015-12-09 ジェンザイム・コーポレーション Gene therapy for neurometabolic disorders
CA2606490C (en) 2005-05-02 2018-02-06 Genzyme Corporation Gene therapy for spinal cord disorders
HUE031156T2 (en) 2006-06-07 2017-06-28 Genzyme Corp Gene therapy for amyotrophic lateral sclerosis and other spinal cord diseases
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US20150182637A1 (en) 2012-06-21 2015-07-02 Association Institut De Myologie Widespread gene delivery of gene therapy vectors

Also Published As

Publication number Publication date
AR061282A1 (en) 2008-08-20
IL241890A0 (en) 2015-11-30
EP3540054A3 (en) 2019-10-09
MX2019004843A (en) 2021-06-15
CN101460621A (en) 2009-06-17
LT2029742T (en) 2016-11-10
TR201906106T4 (en) 2019-05-21
US20100267812A1 (en) 2010-10-21
JP2020079234A (en) 2020-05-28
US9034836B2 (en) 2015-05-19
EP2489733A3 (en) 2012-11-14
JP2018118995A (en) 2018-08-02
PT2489733T (en) 2019-05-27
AR109171A2 (en) 2018-11-07
LT2489733T (en) 2019-05-27
EP2029742A4 (en) 2009-09-30
US20200101138A1 (en) 2020-04-02
MX2008015530A (en) 2009-02-06
EP2489733A2 (en) 2012-08-22
EP3540054A2 (en) 2019-09-18
CA2654292A1 (en) 2007-12-21
US20160067312A1 (en) 2016-03-10
SI2029742T1 (en) 2016-11-30
HUE031156T2 (en) 2017-06-28
US20230364200A1 (en) 2023-11-16
PL2029742T3 (en) 2017-08-31
JP6606215B2 (en) 2019-11-13
SI2489733T1 (en) 2019-06-28
EP2489733B1 (en) 2019-02-13
US11554161B2 (en) 2023-01-17
CA2654292C (en) 2022-01-11
JP2017078071A (en) 2017-04-27
WO2007146046A3 (en) 2008-05-22
JP2015120719A (en) 2015-07-02
MX2023001965A (en) 2023-02-23
RU2008152821A (en) 2010-07-20
CY1118555T1 (en) 2017-07-12
IL195647A (en) 2015-10-29
EP2029742A2 (en) 2009-03-04
CN101460621B (en) 2016-01-27
JP2014012697A (en) 2014-01-23
EP2029742B1 (en) 2016-07-20
IL195647A0 (en) 2009-09-01
MX364444B (en) 2019-04-26
CA3139726A1 (en) 2007-12-21
ES2596885T3 (en) 2017-01-12
PT2029742T (en) 2016-09-09
JP6320489B2 (en) 2018-05-09
JP2009539847A (en) 2009-11-19
PL2489733T3 (en) 2019-08-30
WO2007146046A2 (en) 2007-12-21
ES2725552T3 (en) 2019-09-24
BRPI0711965A2 (en) 2012-01-24
CA3139726C (en) 2026-01-20

Similar Documents

Publication Publication Date Title
HUE044182T2 (en) Gene therapy for the treatment of amyotrophic lateral sclerosis and other spinal disorders
SI3146982T1 (en) Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
IL191772A0 (en) Compounds for the treatment of inflammatory disorders and microbial diseases
IL191637A0 (en) Compounds for the treatment of inflammatory disorders and microbial diseases
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
ZA200900051B (en) Modulators of metabolism and the treatment of disorders related thereto
IL195851A0 (en) Modulators of metabolism and the treatment of disorders related thereto
PL2056842T3 (en) Modified-galactosyl ceramide for the treatment of cancerous diseases
ZA200901523B (en) Use of extracts for the treatment of viral disorders
ZA200801667B (en) Novel pharmaceutical combinations for the treatment of respiratory disorders
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
ZA201001207B (en) Therapeutic formulations for the treatment of cold and flu-like symptoms
EP2004216A4 (en) Agent for the treatment of hormone-dependent disorders and uses thereof
PL1982178T3 (en) Methods for the treatment of affective disorders
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
IL193944A0 (en) The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
HK1120217A (en) The use of beta-aminoalcohols for the treatment of inflammatory disorders and pain
GB0513413D0 (en) The treatment of inflammatory disorders and pain
GB0622476D0 (en) The treatment of inflammatory disorders and pain
GB0609794D0 (en) The treatment of inflammatory disorders and pain
EP2186515A4 (en) Pharmaceutical composition comprising the combination of an anti-depressive agent and an ansiolytic agent for control and treatment of depressive disorders
AU2006906505A0 (en) Agent for the treatment of hormone-dependent disorders and uses thereof
AU2005901420A0 (en) Diagnosis and treatment of disorders
GB0502596D0 (en) The treatment of inflammatory disorders and pain